ArticleFrontiers in oncology2026
Genetic risk stratification reveals distinct first-order radiomic phenotypes in hepatocellular carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Background: Hepatocellular carcinoma (HCC) exhibits significant morphological heterogeneity that has traditionally been attributed to etiological, environmental, and biological factors. Recent evidence suggests, however, that genetic background may influence tumor characteristics and behavior in HCC. Purpose: To investigate associations between established HCC genetic risk factors and first-order radiomic features. Methods: We evaluated a retrospective cohort of 210 patients with HCC who underwent contrast-enhanced MRI and genetic profiling for three established HCC risk variants (PNPLA3 rs738409-G, TM6SF2 rs58542926-T, and MAU2 rs58489806-T). We screened first-order radiomic features in the full cohort and then focused the primary analysis on 77 treatment-naive patients whose tumor morphology had not been modified by therapy. Patients were stratified into at-risk (≥1 risk allele, n=52) and wild-type (no risk alleles, n=25) groups. Eighteen first-order radiomic features were screened using the Mann-Whitney U test and AUC analysis. The leading feature, kurtosis, was then subjected to univariate and multivariate analysis for clinical and imaging features to identify any confounding effect. In addition, a 10-fold cross-validated cutpoint stability, sensitivity analysis, and Cox/Kaplan-Meier survival analysis were also conducted. Results: Among 18 features, kurtosis best distinguished at-risk from wild-type genotypes in treatment-naive patients (AUC = 0.67, p=0.014), with wild-type tumors showing more uniform, sharply peaked intensity patterns. Tumor volume correlated modestly with kurtosis (Spearman's ρ=0.45, p<0.0001), but volume alone did not discriminate genotype (Mann-Whitney U, p=0.3994). The genotype-kurtosis association remained significant after adjusting for volume and shape (ANCOVA, p=0.029) and strengthened after adjusting for nine clinical/demographic covariates (p=0.003), indicating kurtosis reflects biological information beyond tumor size. The empirical cutpoint was stable across 10-fold cross-validation (mean=3.35, SD = 0.05), and results were unchanged in sensitivity analysis. Kurtosis was not associated with overall survival (Cox HR = 1.19, p=0.13). No genotype-related discrimination was observed in the pooled full cohort, consistent with treatment-related alteration of tumor texture. Conclusions: In a cohort of 210 genetically profiled patients with HCC, genotype-related radiomic features were not apparent when treated and untreated tumors were analyzed together. However, restricting the analysis to the treatment-naive subgroup (n=77) revealed tumor kurtosis as a reproducible, biologically plausible first-order imaging correlate of established HCC genetic risk status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.